MY193807A - T-cell receptor and uses thereof - Google Patents

T-cell receptor and uses thereof

Info

Publication number
MY193807A
MY193807A MYPI2018701841A MYPI2018701841A MY193807A MY 193807 A MY193807 A MY 193807A MY PI2018701841 A MYPI2018701841 A MY PI2018701841A MY PI2018701841 A MYPI2018701841 A MY PI2018701841A MY 193807 A MY193807 A MY 193807A
Authority
MY
Malaysia
Prior art keywords
cell receptor
seq
amino acid
acid sequence
set forth
Prior art date
Application number
MYPI2018701841A
Inventor
Steven P Lee
Original Assignee
Cancer Research Tech Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cancer Research Tech Ltd filed Critical Cancer Research Tech Ltd
Publication of MY193807A publication Critical patent/MY193807A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/1774—Immunoglobulin superfamily (e.g. CD2, CD4, CD8, ICAM molecules, B7 molecules, Fc-receptors, MHC-molecules)

Abstract

The present invention relates to a T-cell receptor comprising: a) an alpha chain comprising an amino acid sequence as set forth in SEQ ID No.1 or a functional equivalent thereof; and/or b) a beta chain comprising an amino acid sequence as set forth in SEQ ID No.2 or a functional equivalent thereof; as well as uses thereof including in the treatment of an EBV+ tumour. Figure 1.
MYPI2018701841A 2015-11-16 2016-11-15 T-cell receptor and uses thereof MY193807A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB1520191.6A GB201520191D0 (en) 2015-11-16 2015-11-16 T-cell receptor and uses thereof
PCT/GB2016/053566 WO2017085471A1 (en) 2015-11-16 2016-11-15 T-cell receptor and uses thereof

Publications (1)

Publication Number Publication Date
MY193807A true MY193807A (en) 2022-10-27

Family

ID=55132860

Family Applications (1)

Application Number Title Priority Date Filing Date
MYPI2018701841A MY193807A (en) 2015-11-16 2016-11-15 T-cell receptor and uses thereof

Country Status (6)

Country Link
CN (1) CN108602875B (en)
GB (1) GB201520191D0 (en)
HK (1) HK1258886A1 (en)
MY (1) MY193807A (en)
SG (1) SG11201803942QA (en)
WO (1) WO2017085471A1 (en)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020112815A1 (en) * 2018-11-27 2020-06-04 Duke University Anti-lmp2 tcr-t cell therapy for the treatment of ebv-associated cancers
CN113423724B (en) * 2018-12-27 2023-11-24 深圳华大生命科学研究院 EBV epitope high affinity T cell receptor
CN111848781A (en) * 2019-04-25 2020-10-30 天津亨佳生物科技发展有限公司 Specific T cell receptor aiming at EGFR L858R gene mutation and application thereof
CN113621070A (en) * 2020-05-06 2021-11-09 华夏英泰（北京）生物技术有限公司 T cell antigen receptor, polymer compound thereof, preparation method and application thereof
CN112940108B (en) * 2021-03-19 2022-10-14 河南省肿瘤医院 T cell receptor for identifying EBV antigen and application of T cell receptor
WO2023092452A1 (en) * 2021-11-26 2023-06-01 上海吉倍生物技术有限公司 T cell receptor for identifying ebv lmp2 antigen and use thereof

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4361539A (en) 1980-05-05 1982-11-30 Instrumentation Laboratory Inc. Analysis system
US6750325B1 (en) 1989-12-21 2004-06-15 Celltech R&D Limited CD3 specific recombinant antibody
GB9021679D0 (en) 1990-10-05 1990-11-21 Gorman Scott David Antibody preparation
US5968509A (en) 1990-10-05 1999-10-19 Btp International Limited Antibodies with binding affinity for the CD3 antigen
GB9206422D0 (en) 1992-03-24 1992-05-06 Bolt Sarah L Antibody preparation
CA2523716C (en) 2003-05-31 2014-11-25 Micromet Ag Human anti-human cd3 binding molecules
CA2571957A1 (en) 2004-07-01 2006-01-12 Waratah Pharmaceuticals, Inc. Methods and compositions using cd3 agonists
JP5292550B2 (en) * 2007-03-23 2013-09-18 静岡県 T cell receptor β chain gene and α chain gene
CN101182531B (en) * 2007-11-09 2010-06-02 暨南大学 Recombination plasmid related with EB virus specificity TCR gene and method for constructing anti-EBV specific CTL
GB0917090D0 (en) * 2009-09-29 2009-11-11 Ucl Biomedica Plc T-cell receptor
SI2618835T1 (en) * 2010-09-20 2017-10-30 Biontech Cell & Gene Therapies Gmbh Antigen-specific t cell receptors and t cell epitopes
GB201314404D0 (en) * 2013-08-12 2013-09-25 Immunocore Ltd T Cell Receptors

Also Published As

Publication number Publication date
HK1258886A1 (en) 2019-11-22
CN108602875B (en) 2022-08-12
SG11201803942QA (en) 2018-06-28
GB201520191D0 (en) 2015-12-30
WO2017085471A1 (en) 2017-05-26
CN108602875A (en) 2018-09-28

Similar Documents

Publication Publication Date Title
MY193807A (en) T-cell receptor and uses thereof
MD4733C1 (en) Anti-TIGIT antibodies
TN2017000085A1 (en) Polypeptide having a polyester degrading activity and uses thereof
BR112016024352A2 (en) "recombinant listeria strain, recombinant listeria, pharmaceutical composition, and methods of inducing an immune response against a tumor or cancer in a human and listeria individual"
MX2017001279A (en) Flagellin compositons and uses.
NZ603901A (en) Vectors and sequences for the treatment of diseases
MA39717A (en) Methods and compositions for increasing a t-effector cell to regulatory t cell ratio
PH12015501983B1 (en) Peptides and compositions for treatment of joint damage
NZ708727A (en) Conjugate compounds
MX2017009595A (en) Anti-senescence compounds and uses thereof.
PH12019502036A1 (en) Peptides and methods for the treatment of diabetes
MX2017006437A (en) Spiro-isoquinoline-1,4'-piperidine compounds having multimodal activity against pain.
MX2018005872A (en) Nucleic acid prodrugs.
EP3925968A3 (en) Hsp70-derived peptide, pharmaceutical composition for treating or preventing cancer using same, immunity inducer, and method for producing antigen-presenting cell
NZ729514A (en) Therapeutic multi-peptides t specific immune therapy for treatment of brain metastasis
MX2021008225A (en) Compositions and methods for treatment of abnormal cell growth.
EA201690966A1 (en) NEW CONNECTION FOR THE TREATMENT OF HEAVY HYPOGLYCEMIA
MY174711A (en) Novel anti-fc-gamma receptor iib antibodies and uses thereof
MX362058B (en) Synthetic pntx(19) peptide, pharmaceutical compositions and use.
GB201118201D0 (en) Novel peptides
MY181148A (en) Microorganisms for producing diamine and process for producing diamine using them
MY178471A (en) Microorganisms for producing diamine and process for producing diamine using them
MX2019012083A (en) Novel peptide based pcsk9 vaccine.
MX2019001320A (en) Composition and use of a peptide.
CU20210061A7 (en) VACCINE COMPOSITION COMPRISING THE ALPHA 3 DOMAIN OF MICA/B FOR THE TREATMENT OF CANCER